Site Map Press Room Careers
Financial
Financial Results
FY 2007 - 2008
FY 2006 - 2007
FY 2005 - 2006
FY 2004 - 2005
FY 2003 - 2004
FY 2002 - 2003
Q1 2002 - 2003
Q2 2002 - 2003
Q3 2002 - 2003
FY 2001 - 2002
FY 2000 - 2001
Financial Highlights
Annual Reports
Dividend Record
Business Drivers
Investors
Shareholding Pattern
Share Performance
Contact Person
Frequently Asked Questions
 
Unaudited Financial Results for the Quarter ended 31st December, 2002

(Rs. in Mio)
  Three Months Ended Nine Months Ended Year ended

Particulars

 (Unaudited) (Unaudited) (Audited)
  31.12.2002 31.12.2001 31.12.2002 31.12.2001 31.03.2002
Net Sales/Income from Operations 3015.6 2817.8 8536.4 7186.7 10377.2
Other Income 1.6 34.4 68.2 119.5

146.8
Total Income 3017.2 2852.2 8604.6 7306.2 10524
Expenditure          
a. (Increase) / Decrease in Stock in Trade
-17.4 -117.4 -204.1 30.8 209.3
 b. Consumption of Raw Materials 1959 1939.1 5670.7 4662.1 6671.7
 c. Staff Cost 72.2 64.1 188.4 181.8 251.7
 d. Other Expenditure 571.4 555.5 1721.6 1440.6 2020.9
Total expenditure 2585.2 2441.3 7376.6 6315.3 9153.6
Profit Before Depreciation, Interest & Tax 432 410.9 1228 990.9 1370.4
Interest 91.9 105 312 314.5 423.9
Depreciation 46.1 41.2 128.7 118.3 158.1
Profit before extra-ordinary item & taxation
Add: Extra-ordinary item		 294

--		 264.7

--		 787.3

--		 558.1

--		 788.4

100.0
Profit after extra ordinary item & before taxation 294
 264.7
 787.3
 558.1
 888.4
Provision for Taxation
a) Current Tax
b) Deferred Tax
c) Tax adjustments of previous years
57
25.5
--
49.9
13.8
--
165
54.6
--
87
12
--
153.7
37.9
11.7
Net Profit 211.5 201 567.7 459.1 685.1
Paid-up Equity Share Capital (Face Value Rs.10) 232.5 202 232.5 202 206.7
Reserves excluding Revaluation Reserves -- -- -- -- 3406.9
Basic Earnings per share(Rs.) (not annualised) 9.1 9.95 25.21 22.73 33.89
Dilluted Earnings per share(Rs.) 9.1 -- 25.21 -- 33.89
Aggregate of Non-promoter Shareholding          
a. Number. of Shares     8911660 6856864 6978167
b. Percentage of Shareholding     38.33 33.94 33.76
Segmentwise Revenue Results and Capital Employed Under Clause 41 of the Listing Agreement

(Rs. in Mio)

Particulars

 Three months ended Nine months ended Year ended
(Unaudited) (Unaudited) (Audited)
  31.12.2002 31.12.2001 31.12.2002 31.12.2001 31.03.2002
1. Segment Revenue          
a. Bulk Drugs & Drug Intermediaries
2878.7 2666.5 8334.1 6781.4 10855.9
b.  Formulation 180.7 222.1 477.2 650.5 1061.7
c.  Research & Development -- -- -- -- --
Total 3059.4 2888.6 8811.3 7431.9 11917.6
Less: Inter segment revenue 41.8 68.1 254.7 239.7 1433
Net Sales/Income from operation 3017.6 2820.5 8556.6 7192.2 10484.6
2. Segment Results Profit(+) / Loss(-) before tax and interest
         
a. Bulk Drugs & Drug Intermediaries
421.6 372.4 1190.4 870.8 1444.6
b.  Formulation 37.7 12.8 67.7 16.3 227.8
c.  Research & Development -38.5 -15.8 -83.9 -49.1 -60.5
Total 420.8 369.4 1174.2 838 1611.9
Less:  (I) Interest (Net) 79.2 102.2 269 292.4 392.6
(ii) Other un-allocable expenditure 47.6 2.5 117.9 -12.5 330.9
    net of unallocable income          
Total Profit before tax 294 264.7 787.3 558.1 888.4
3. Capital Employed          
a .  Bulk Drugs 5134.6 5343.1 5134.6 5343.1 3870.9
b.  Formulation 1312.9 646.2 1312.9 646.2 1180
c.  Research & Development 211.3 176.2 211.3 176.2 173.9
Total 6658.8 6165.5 6658.8 6165.5 5224.8
1. The above results were taken on record by the Board of Directors at their meeting held on 31st January 2003.
2. The first phase of commercial production commenced at its new plant near Vizag during the quarter.
For and on behalf of the Board
Sd/-
Place: Hyderabad K.Nityananda Reddy
Date : 31.01.2003 Managing Director
Site Map Press Room Careers